Sequence information
DRAVP ID DRAVPc020
Name Interferon beta-1b
Sequence
Molecular Formula C908H1408N246O253S6
Condition/Disease HIV infection, COVID-19
Group Approved
Type Protein
Description Interferon beta-1b is a form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms.
Active sequence/Structure
External Links
DrugBank Accession Number DB00068
Pubchem ID 46504458
CHEMBL ID CHEMBL1201563
UNII TTD90R31WZ
CAS 145155-23-3
Reference 9890522
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT04276688 | Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | Coronavirus Disease 2019 (COVID‑19) / Novel Coronavirus Infection Treatment | Completed | Phase 2 | The University of Hong Kong |
| NCT04343768 | An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial (COVIFERON) | Coronavirus Disease 2019 (COVID‑19) Treatment | Completed | Phase 2 | Shahid Beheshti University of Medical Sciences |
| NCT00002238 | Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen | Human Immunodeficiency Virus (HIV) Infections Treatment | Completed | Phase 3 | Bayer |
